[HTML][HTML] Efficacy and safety of Molnupiravir in COVID-19 patients: A systematic review
Background Molnupiravir is an oral antiviral drug that received Emergency Use
Authorization in three countries for the treatment of mild COVID-19. The aim of this …
Authorization in three countries for the treatment of mild COVID-19. The aim of this …
[HTML][HTML] Potential herb–drug interactions between anti-COVID-19 drugs and traditional Chinese medicine
L Ye, S Fan, P Zhao, C Wu, M Liu, S Hu, P Wang… - … Pharmaceutica Sinica B, 2023 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide. Effective treatments against …
syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide. Effective treatments against …
[HTML][HTML] Development and validation of molnupiravir assessment in bulk powder and pharmaceutical formulation by the RP-HPLC-UV method
AM Annadi, NM El Zahar, NEDA Abdel-Sattar… - RSC …, 2022 - pubs.rsc.org
An accurate, sensitive and selective RP-HPLC-UV method has been established for the
estimation of Molnupiravir (MOL) in pure bulk powder and pharmaceutical formulation …
estimation of Molnupiravir (MOL) in pure bulk powder and pharmaceutical formulation …
[HTML][HTML] Evolutionary safety of lethal mutagenesis driven by antiviral treatment
Nucleoside analogs are a major class of antiviral drugs. Some act by increasing the viral
mutation rate causing lethal mutagenesis of the virus. Their mutagenic capacity, however …
mutation rate causing lethal mutagenesis of the virus. Their mutagenic capacity, however …
[HTML][HTML] The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review
Background Throughout the time of the global pandemic of SARS-CoV-2 virus, there has
been a compelling necessity for the development of effective antiviral agents and …
been a compelling necessity for the development of effective antiviral agents and …
Rapid review and meta‐analysis of adverse events associated with molnupiravir in patients with COVID‐19
Aims The aim of this study was to evaluate the safety profile of molnupiravir in COVID‐19
patients. Methods PubMed, Cochrane Library, medRxive and Google Scholar were …
patients. Methods PubMed, Cochrane Library, medRxive and Google Scholar were …
[HTML][HTML] How to use COVID-19 antiviral drugs in patients with chronic kidney disease
Antiviral drugs such as Remdesivir (Veklury), Nirmatrelvir with Ritonavir (Paxlovid),
Azvudine, and Molnupiravir (Lagevrio) can reduce the risk for severe and fatal Coronavirus …
Azvudine, and Molnupiravir (Lagevrio) can reduce the risk for severe and fatal Coronavirus …
[HTML][HTML] Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model
DM Johnson, T Brasel, S Massey, T Garron, M Grimes… - Antiviral research, 2023 - Elsevier
Abstract Molnupiravir (EIDD-2801) is a prodrug of a ribonucleoside analogue that is
currently being used under a US FDA emergency use authorization for the treatment of mild …
currently being used under a US FDA emergency use authorization for the treatment of mild …
[HTML][HTML] Review on molnupiravir as a promising oral drug for the treatment of COVID-19
E Zarenezhad, M Marzi - Medicinal Chemistry Research, 2022 - Springer
During the COVID-19 pandemic, various drug candidates have been developed,
molnupiravir (MK-4482 and EIDD-2801), which is a new orally anti-viral agent under …
molnupiravir (MK-4482 and EIDD-2801), which is a new orally anti-viral agent under …
[HTML][HTML] Real-world clinical outcomes of molnupiravir for the treatment of mild to moderate COVID-19 in adult patients during the dominance of the Omicron variant: a …
C Huang, TL Lu, L Lin - Antibiotics, 2023 - mdpi.com
Introduction: The therapeutic impact of molnupiravir in the Omicron variant phase is
unknown. The goal of the current meta-analysis was to compare the real-world clinical …
unknown. The goal of the current meta-analysis was to compare the real-world clinical …